Nemaura Medical, Inc. · OTC:NMRD

Nemaura Medical — Technical Presentation (December 2018)

10 slides from Nemaura Medical's technical presentation, Dec 18, 2018

  1. Slide 1: Clinical presentation of sugarBEAT®

    Clinical presentation of sugarBEAT® A Prospective Single Centre Evaluation Nemaura Medical of the Accuracy and safety of the sugarBEAT® Non-invasive Continuous Glucose Monitor (CGM) System Better Diagnostics for Life NASDAQ: NMRD 18th December 2018 Author Dr T Rahman, MBBS, PhD Clinical research Man

  2. Slide 2: Study Objective

    Study Objective A EU based study to determine the safety and accuracy of the sugarBEAT® CGM for FDA De Novo submission 2

  3. Slide 3: Study Design

    Prospective single arm, single centre study Abbott Freestyle Optimum Neo BGM used as reference for Home Study Portion NEMAURA MEDICAL Accuracy and safety assessed over 7 consecutive Venous blood samples used as reference for in-clinic wear days, consisting of 3 non-consecutive in-clinic portion of s

  4. Slide 4: Study Methods

    Study Methods –– –– –– –– –– –– –– –– –– 4

  5. Slide 5: Accuracy vs Glucose Range In-clinic 1-point calibration

    Accuracy vs Glucose Range In-clinic 1-point calibration The proportion of agreement is 76.098% Table 1.2 sugarBEAT® system agreement (with 95% confidence interval from 0.75382 proportion with reference glucose to 0.76814). Table 1. shows the proportion measurement in different glucose ranges. of agr

  6. Slide 6: Accuracy vs Glucose Range In-clinic portion of study 1-point calibration

    Accuracy vs Glucose Range In-clinic portion of study 1-point calibration Glucose range Number of Within ±10% or Within ±15% or Within ±20% or Within ±30% or Within ±40% or Outside±40% (mg/dl) paired points ±10 mg/dl ±15 mg/dl ±20 mg/dl ±30 mg/dl ±40 mg/dl or ±40 mg/dl (MARD) (MARD) (MARD) (MARD) (MA

  7. Slide 7: Accuracy vs Glucose Range In-clinic 2-point calibration

    Accuracy vs Glucose Range In-clinic 2-point calibration The proportion of agreement is 78.33% Table 1.2 sugarBEAT® system agreement (with 95% confidence interval from 0.77646 proportion with reference glucose to 0.79032). Table 1. shows the proportion measurement in different glucose ranges. of agre

  8. Slide 8: Accuracy vs Glucose Range In-clinic portion of study 2-point calibration

    Accuracy vs Glucose Range In-clinic portion of study 2-point calibration Glucose range Number of Within ±10% or Within ±15% or Within ±20% or Within ±30% or Within ±40% or Outside±40% (mg/dl) paired points ±10 mg/dl ±15 mg/dl ±20 mg/dl ±30 mg/dl ±40 mg/dl or ±40 mg/dl (MARD) (MARD) (MARD) (MARD) (MA

  9. Slide 9: Safety Evaluation

    Safety Evaluation Past Studies Current Studies –– –– –– 9

  10. Slide 10: Conclusion

    Conclusion The analysis indicates the in clinic portion of the study shows accuracy levels, as measured using overall nominal MARD, as comparable to previously reported data and within the targets for the intended indications. 10

Nemaura Medical — Technical Presentation (December 2018) on 6ix